Jason Zhang

In a report published Friday, Edison Investment Research analyst Jason Zhang commented on recent developments related to Halozyme Therapeutics (NASDAQ: HALO). In the report, Edison Investment Research noted, “With a positive CHMP opinion received for Herceptin SC, Halozyme is moved a step closer...